ARTICLE | Company News
Sirona Biochem endocrine/metabolic news
July 2, 2012 7:00 AM UTC
Sirona retained Bloom Burton to develop a strategic plan to expand Sirona's carbohydrate chemistry platform into new therapeutic areas. Sirona's technology enhances the stability and bioavailability of carbohydrate-based molecules by adding fluorine atoms. Sirona's SBM-TFC-039 is a sodium-glucose cotransporter (SGLT) inhibitor in preclinical testing to treat Type II diabetes. Sirona acquired SBM-TFC-039 and chemistry platform through its 2011 acquisition of TFChem S.A.S. Details were not disclosed (see BioCentury, April 11, 2011). ...